Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Alumni
  • Login
  • Volunteer
  • Clubs
  • Reunions
  • Bulletin
  • Class Notes
  • Help
  • Give Now
  • Stories
  • Alumni Directory
  • Lifelong Learning
  • Careers
  • Programs & Events
  • Giving
  • …→
  • Harvard Business School→
  • Alumni→
  • Stories→

Stories

Stories

16 Nov 2020

Moderna Announces Promising Vaccine Trial Results

Re: Stefan Bancel (MBA 2000)
Topics: Health-Health PandemicsHealth-Health Testing and TrialsInnovation-Technological InnovationScience-Science-Based Business
ShareBar

Stéphane Bancel (MBA 2000, AMP 170)
Photo by Richard Howard

Stéphane Bancel (MBA 2000, AMP 170)
Photo by Richard Howard

Moderna released promising news on the progress of their coronavirus vaccine this morning, noting that trials showed it to be 94.5% effective. “In this pandemic, what has been awful from a public health standpoint, an economic standpoint, is the worry people have to get so sick they have to go to the hospital—so sick they have to get to the ICU and have a high risk of dying,” Moderna CEO Stephane Bancel (MBA 2000) told The Washington Post. “If a [vaccine] could prevent 95 percent of people to not get disease, but to not get severe disease, that would be a game-changer: the impact on hospitals, the impact on people’s psyche and the impact on deaths.”

"These are obviously very exciting results," Dr. Anthony Fauci told CNN. "It's just as good as it gets—94.5% is truly outstanding."

A December HBS Alumni Bulletin article tracks Moderna’s path to this discovery, which began in January of this year, when it developed a treatment that went concept to clinical-trial-ready in a record-breaking 42 days. The article lays out just how radically fast the Moderna development timeline has been relative to previous vaccines—which have taken up to 13 years to come to fruition. Regarding the competitors in the race to develop a vaccine, though, Bancel makes a point in the December article that is increasingly relevant today as coronavirus cases spike nationwide: “We’re not racing against each other,” he told the Bulletin. “We’re racing the virus.”

READ MORE

ShareBar

Featured Alumni

Stefan Bancel
MBA 2000

Post a Comment

Featured Alumni

Stefan Bancel
MBA 2000

Related Stories

    • 16 Dec 2021
    • HBS Clubs

    A Global Alumni Response to the Pandemic

    By: Margie Kelley
    • 06 Dec 2021
    • HBS Alumni Bulletin

    Wheels Up

    Re: Dalton Philips (MBA 1998); By: Julia Hanna
    • 27 Sep 2021
    • Making A Difference

    Sewn with Love

    Re: Kikka Hanazawa (MBA 2002)
    • 07 Sep 2021
    • HBS Alumni Bulletin

    My Pandemic Pivot

    Re: Calley Means (MBA 2015); Taru Kapoor (MBA 2015)

More Related Stories

Stories Featuring Stefan Bancel

    • 17 Jun 2021
    • Newsweek

    A Conversation With Moderna Leader Stéphane Bancel

    Re: Stefan Bancel (MBA 2000)
    • 20 Jan 2021
    • HBS Clubs

    In Conversation with Stéphane Bancel

    Re: Stefan Bancel (MBA 2000)
    • 24 Sep 2020
    • HBS Alumni Bulletin

    The Race for a Vaccine

    Re: Stefan Bancel (MBA 2000); Kate Bingham (MBA 1991); Gary P. Pisano (Harry E. Figgie, Jr. Professor of Business Administration Senior Associate Dean for Faculty Promotions and Tenure); By: April White

More Stories Featuring Stefan Bancel

 
 
 
 
  • Explore
  • Explore
  • Explore
  • Explore
  • Explore
  • Explore
  • Explore
  • Explore
  • Explore
ǁ
Campus Map
External Relations
Harvard Business School
Teele Hall
Soldiers Field
Boston, MA 02163
Phone: 1.617.495.6890
Email: alumni+hbs.edu
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
  • Terms of Use
Copyright © President & Fellows of Harvard College